From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
Cell line | Hystotype | Mutational status | |||
---|---|---|---|---|---|
TP53 | EGFR | KRAS | Other mutations/molecular alterations | ||
Calu-6 | anaplastic carcinoma | mut | wt | Q61K | JAK1, BRCA1, p16INK4A methylation |
SK-Lu-1 | adenocarcinoma | mut | wt | G12D | KIT, CSF3R, FLT4 |
NCI-H1975 | adenocarcinoma | mut | L858R + T790 M | wt | PDGFRA, PIK3CA |
NCI-H2228 | adenocarcinoma | mut | wt | wt | ALK translocation, PDGFRA, RB |